Profound Medical (TSE:PRN) Trading 2.3% Higher – Should You Buy?

Profound Medical Corp. (TSE:PRN)’s stock price rose 2.3% on Tuesday . The stock traded as high as C$9.82 and last traded at C$9.82. 2,101 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 15,850 shares. The stock had previously closed at C$9.60.

Profound Medical Stock Down 2.2%

The company has a debt-to-equity ratio of 12.56, a current ratio of 6.56 and a quick ratio of 14.98. The company has a market cap of C$350.30 million, a PE ratio of -7.77 and a beta of 1.26. The business’s 50 day moving average is C$9.60 and its 200-day moving average is C$9.46.

Profound Medical (TSE:PRN) last announced its quarterly earnings data on Thursday, May 7th. The company reported C$0.26 earnings per share for the quarter. The business had revenue of C$7.42 million for the quarter. Profound Medical had a negative net margin of 206.94% and a negative return on equity of 78.75%. As a group, analysts predict that Profound Medical Corp. will post -1.9000001 EPS for the current year.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.